MedTrace Logo

Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

NCT07550231 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.

Conditions

  • Osteoarthritis of the Knees

Interventions

DRUG

AD-211-L

Per oral, 1 tablet twice daily during the treatment period.

DRUG

AD-211-M

Per oral, 1 tablet twice daily during the treatment period.

DRUG

AD-211-H

Per oral, 1 tablet twice daily during the treatment period.

DRUG

AD-2113

Per oral, 1 tablet twice daily during the treatment period.

DRUG

Placebo to AD-211-L/M

Per oral, 1 tablet twice daily during the treatment period.

DRUG

Placebo to AD-211-H

Per oral, 1 tablet twice daily during the treatment period.

DRUG

Placebo to AD-2113

Per oral, 1 tablet twice daily during the treatment period.

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Jung Yoon Choi · Daegu Catholic University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-03-31
Completion
2027-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07550231 on ClinicalTrials.gov